A controlled trial of the cost benefit of computerized bayesian aminoglycosde administration

Michael E. Burton, Cynthia L. Ash, Donald P. Hill, TaRee Handy, Marvin D. Shepherd, Michael Vasko

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

We studied the effect of a bayesian pharmacokinetic dosing program on the outcome of aminoglycroside therapy in patients with clinical infections. Patients were randomized to a control (dosing based on physician choice; n = 75) or experimental group (dosing based on the bayesian program; n = 72). Both groups used serum ammoglycoside concentration data when maid dosing decisions. Improved response rates were seen in the experimental (60%; 42168) compared with the control group (48%; 36 68). A higher, but not statistically significant, incidence of toxicity was found in the control ( 7 75; 9.7%) versus the experimental group ( 4 72; 5.1%). Mean length of total hospital stay was significantly longer for patients in the control group (20.3 days) compared with the experimental group (16.0 days) (p = 0.028). The variables from multivariate analysis with a significant impact on length of stay were patient group and length of ammoglycoside therapy. On the basis of a reduced length of stay, a potential cost savings of $1311 per patient can be achieved .

Original languageEnglish
Pages (from-to)685-694
Number of pages10
JournalClinical Pharmacology and Therapeutics
Volume49
Issue number6
StatePublished - Jun 1991

Fingerprint

Cost-Benefit Analysis
Length of Stay
Control Groups
Cost Savings
Multivariate Analysis
Pharmacokinetics
Physicians
Incidence
Therapeutics
Infection
Serum

ASJC Scopus subject areas

  • Pharmacology

Cite this

A controlled trial of the cost benefit of computerized bayesian aminoglycosde administration. / Burton, Michael E.; Ash, Cynthia L.; Hill, Donald P.; Handy, TaRee; Shepherd, Marvin D.; Vasko, Michael.

In: Clinical Pharmacology and Therapeutics, Vol. 49, No. 6, 06.1991, p. 685-694.

Research output: Contribution to journalArticle

Burton, ME, Ash, CL, Hill, DP, Handy, T, Shepherd, MD & Vasko, M 1991, 'A controlled trial of the cost benefit of computerized bayesian aminoglycosde administration', Clinical Pharmacology and Therapeutics, vol. 49, no. 6, pp. 685-694.
Burton, Michael E. ; Ash, Cynthia L. ; Hill, Donald P. ; Handy, TaRee ; Shepherd, Marvin D. ; Vasko, Michael. / A controlled trial of the cost benefit of computerized bayesian aminoglycosde administration. In: Clinical Pharmacology and Therapeutics. 1991 ; Vol. 49, No. 6. pp. 685-694.
@article{b2ad1ac0b99749c59fc3d4018c15f3f2,
title = "A controlled trial of the cost benefit of computerized bayesian aminoglycosde administration",
abstract = "We studied the effect of a bayesian pharmacokinetic dosing program on the outcome of aminoglycroside therapy in patients with clinical infections. Patients were randomized to a control (dosing based on physician choice; n = 75) or experimental group (dosing based on the bayesian program; n = 72). Both groups used serum ammoglycoside concentration data when maid dosing decisions. Improved response rates were seen in the experimental (60{\%}; 42168) compared with the control group (48{\%}; 36 68). A higher, but not statistically significant, incidence of toxicity was found in the control ( 7 75; 9.7{\%}) versus the experimental group ( 4 72; 5.1{\%}). Mean length of total hospital stay was significantly longer for patients in the control group (20.3 days) compared with the experimental group (16.0 days) (p = 0.028). The variables from multivariate analysis with a significant impact on length of stay were patient group and length of ammoglycoside therapy. On the basis of a reduced length of stay, a potential cost savings of $1311 per patient can be achieved .",
author = "Burton, {Michael E.} and Ash, {Cynthia L.} and Hill, {Donald P.} and TaRee Handy and Shepherd, {Marvin D.} and Michael Vasko",
year = "1991",
month = "6",
language = "English",
volume = "49",
pages = "685--694",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - A controlled trial of the cost benefit of computerized bayesian aminoglycosde administration

AU - Burton, Michael E.

AU - Ash, Cynthia L.

AU - Hill, Donald P.

AU - Handy, TaRee

AU - Shepherd, Marvin D.

AU - Vasko, Michael

PY - 1991/6

Y1 - 1991/6

N2 - We studied the effect of a bayesian pharmacokinetic dosing program on the outcome of aminoglycroside therapy in patients with clinical infections. Patients were randomized to a control (dosing based on physician choice; n = 75) or experimental group (dosing based on the bayesian program; n = 72). Both groups used serum ammoglycoside concentration data when maid dosing decisions. Improved response rates were seen in the experimental (60%; 42168) compared with the control group (48%; 36 68). A higher, but not statistically significant, incidence of toxicity was found in the control ( 7 75; 9.7%) versus the experimental group ( 4 72; 5.1%). Mean length of total hospital stay was significantly longer for patients in the control group (20.3 days) compared with the experimental group (16.0 days) (p = 0.028). The variables from multivariate analysis with a significant impact on length of stay were patient group and length of ammoglycoside therapy. On the basis of a reduced length of stay, a potential cost savings of $1311 per patient can be achieved .

AB - We studied the effect of a bayesian pharmacokinetic dosing program on the outcome of aminoglycroside therapy in patients with clinical infections. Patients were randomized to a control (dosing based on physician choice; n = 75) or experimental group (dosing based on the bayesian program; n = 72). Both groups used serum ammoglycoside concentration data when maid dosing decisions. Improved response rates were seen in the experimental (60%; 42168) compared with the control group (48%; 36 68). A higher, but not statistically significant, incidence of toxicity was found in the control ( 7 75; 9.7%) versus the experimental group ( 4 72; 5.1%). Mean length of total hospital stay was significantly longer for patients in the control group (20.3 days) compared with the experimental group (16.0 days) (p = 0.028). The variables from multivariate analysis with a significant impact on length of stay were patient group and length of ammoglycoside therapy. On the basis of a reduced length of stay, a potential cost savings of $1311 per patient can be achieved .

UR - http://www.scopus.com/inward/record.url?scp=0025817581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025817581&partnerID=8YFLogxK

M3 - Article

C2 - 1905602

AN - SCOPUS:0025817581

VL - 49

SP - 685

EP - 694

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 6

ER -